Brian Michael, MD
Endocrinology, Diabetes & Metabolism · Gettysburg, PANPI 1942237722
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 70.9% of it on its own, with 52 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 903 payments — averaging $69.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$45K
- Corcept Therapeutics$3K
- Novo Nordisk$3K
- AbbVie$2K
- Lilly USA, LLC$1K
- Tandem Diabetes Care, Inc.$996
- plus $8K from 47 others
What the payments were for
- Consulting fees$5,8509%
- Speaking & faculty fees$31,75850%
- Travel & lodging$7,64412%
- Food & beverage$17,57228%
- Education$1630%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$37,702
- Korlym$2,938
- Synthroid$1,350
- t:slim X2 insulin pump$850
- CeQur Simplicity$601
- V-GO$139
How this compares
$63,046 in reported general payments places this provider in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 328 | $393,223 |
| OzempicSemaglutide | 214 | $370,286 |
| JardianceEmpagliflozin | 230 | $236,891 |
| Tresiba Flextouch U-200Insulin Degludec | 64 | $145,861 |
| TrulicityDulaglutide | 64 | $81,288 |
| KerendiaFinerenone | 66 | $78,349 |
| Tresiba Flextouch U-100Insulin Degludec | 88 | $61,960 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $49,645 |
| JanuviaSitagliptin Phosphate | 41 | $47,485 |
| Repatha SureclickEvolocumab | 66 | $47,034 |
| FarxigaDapagliflozin Propanediol | 51 | $43,326 |
| Novolog FlexpenInsulin Aspart | 92 | $38,236 |
| RybelsusSemaglutide | 18 | $34,824 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 35 | $32,410 |
| Cinacalcet Hcl | 59 | $30,769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,490 | $474,511392 claims |
| Novo NordiskOzempic, Rybelsus | $2,574 | $405,110232 claims |
| Boehringer IngelheimJardiance, Tradjenta | $388 | $254,997258 claims |
| BayerKerendia | $453 | $78,34966 claims |
| MerckJanuvia | $14 | $47,48541 claims |
| AstraZenecaFarxiga | $354 | $43,32651 claims |
| AbbVieSynthroid | $2,218 | $23,691234 claims |
| AmgenProlia | $44,683 | $21,78313 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $262 | $6,250310 claims |
| PfizerLevoxyl | $198 | $1,96552 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Gettysburg
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Geraldo SaavedraWhitehall$698K
- Jane MayrinPhiladelphia$628K
- Stephan KowalykGreensburg$591K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
- James DickeHanover$425K
- Mitchell LazarPhiladelphia$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.